AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05220527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone plus hyruan
Description: triamcinolone plus hyruan injections, one time per week, for 3 weeks
Study NCT05220527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitagen plus hyruan
Description: vitagen plus hyruan injections, one time per week, for 3 weeks
Study NCT05220527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline plus hyruan
Description: normal saline plus hyruan injections, one time per week, for 3 weeks
Study NCT04671849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM1803-1A
Description: SIM1803-1A will be administered orally as tablets at a given dose once daily in continuing 21-days cycles.
Study NCT02519933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mNT-BBAVF
Description: mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
Study NCT02519933 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BCAVF
Description: BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
Study NCT02858674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pop Up Interruption Alert
Description: Traditional Pop Up Alert used in Epic
Study NCT02858674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Side Bar Non Interruptive Provider Checklist
Description: Noninterruptive alert that sits in the checklist
Study NCT01862042 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up diary and questionnaire
Description: A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
Study NCT03930654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPrEP
Description: * iPrEP transforms the standard emergency department (ED) visit experience through an intervention presented as a standard assessment that is equipped to: 1) increase knowledge of HIV transmission and 2) provide information on how to reduce an individual's risk for HIV.~* Women will receive the iPrEP intervention on an iPAD Air tablet device~* iPrEP serves a dual role as a data collection instrument and an intervention--the survey incorporates brief, informational messages into a traditional survey instrument~* iPrEP uses qualitative themes~* iPrEP is divided into sections addressing factors with historical success at predicting pre-exposure prophylaxis (PrEP) adherence~* Scales chosen to measure themes and sections were retained from the original HIV Prevention Trials Network (HPTN) 073 instrument~* Scales were modified (in some cases) for cultural competency and tailoring to women
Study NCT03930654 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: * Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies
Study NCT03930654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: * Women will receive usual care~* Usual care includes an assessment visit with an emergency department (ED)-assigned social worker who specializes in substance use~* Social worker will offer a list of substance abuse treatment referral agencies
Study NCT01527864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated endostatin and Paclitaxel-Carboplatin
Description: Dosage：10mg/m2
Study NCT01527864 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo and Paclitaxel-Carboplatin
Description: Dosage：10mg/m2
Study NCT01757678 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ICA (Invasive Coronary Angiography)
Description: Per the protocol, patients will have an Invasive Coronary Angiography.
Study NCT01757678 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FFR (Fractional Flow Reserve)
Description: Per the protocol, patients will have a Fractional Flow Reserve procedure.
Study NCT01757678 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: cCTA (coronary computed tomography angiography)
Description: Per the protocol, patients will have a coronary computed tomography angiography.
Study NCT01757678 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FFRct Analysis (Fractional Flow Reserve Computed Tomography)
Description: Per the protocol, patients will have a fractional flow reserve computed tomography.
Study NCT02788942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removing from Epigastric port
Description: The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
Study NCT03848182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TT vaccine booster
Description: One human TT childhood vaccine booster will be administered on day 8
Study NCT03443674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCB-313
Description: Lyophilized powder in a single-use vial
Study NCT00848055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn168 intravenous infusion
Description: single dose intravenous infusion
Study NCT00848055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AbGn168 subcutaneous injection
Description: single dose subcutaneous injection
Study NCT00750737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: 200 mg three times daily by mouth up to 6 weeks (Days 1-42)
Study NCT00750737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABLC
Description: 7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
Study NCT01714427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
Study NCT01714427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sterile isotonic saline
Description: two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
Study NCT03345108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Adhesive Cream (Conventional Application)
Description: The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05g for the maxillary and 0.60±0.05g for the mandibular dentures.
Study NCT03345108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Denture Adhesive (Continuous Strip Application)
Description: The adhesive cream will be extruded from a pre-dosed syringe. 1.6 g of adhesive per treatment will be applied to each participant's dentures. This dose will be split as 1.00±0.05 g for the maxillary and 0.60±0.05 g for the mandibular dentures.
Study NCT03345108 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Adhesive
Description: No adhesive applied.
Study NCT02868697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TauroLock U 25000
Description: taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
Study NCT02868697 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: (TauroLock Hep500)
Description: 1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
Study NCT05284942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil combined with oral prednisone
Description: Mycophenolate mofetil oral 500mg twice a day combined with standard of care of oral prednisone 5mg-15mg/day from baseline to week 108
Study NCT04408690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Immediate anterior cruciate ligament reconstruction
Description: No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury.
Study NCT04408690 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
Study NCT04408690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
Study NCT04408690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional delayed anterior cruciate ligament reconstruction
Description: If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury.
Study NCT03036137 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
Study NCT03036137 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Sham tDCS sessions will last 20 minutes
Study NCT00775879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction with Sevoflurane
Study NCT00775879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction with Sevoflurane
Study NCT03342768 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Smartphone-based messages
Description: For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research.
Study NCT03342768 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone-based messages
Description: For the TID arm, the messages' contents include the tobacco industry's (TI's) anti-smoking campaigns that made smoking more grown-up and more appealing to youth; the TI's role in smoking in movies; etc.~For the sugar sweetened beverage (SSB) arm, the messages' contents include the disease conditions linked to SSBs, and the interference of sugar industry in scientific research.
Study NCT03591640 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood test
Description: Standard blood test
Study NCT02757560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SFA diet
Description: SFA versus control diet
Study NCT02757560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUFA diet
Description: MUFA versus control diet
Study NCT02619201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
Study NCT02619201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoclopramide
Description: An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
Study NCT02757560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CARB diet
Description: CARB versus control diet
Study NCT03852511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NG-350A
Description: NG-350A is oncolytic adenoviral vector which expresses a full length agonist anti-CD40 antibody at the site of virus replication.
Study NCT03218501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SK-1405 high dose
Description: SK-1405 high dose is to be administered orally once daily for 2 weeks
Study NCT04131335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEONTM Repair
Description: Lubricating eye drops
Study NCT04131335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine post-operative eye drops used.
Description: Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
Study NCT04131335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine post-operative eye drops used.
Description: Dexamethasone 0.1% eye drops QDS for 4 weeks Chloramphenicol 0.5% eye drops QDS for 1 week
Study NCT04971876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLR-1
Description: Initial injection of HLR-1 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL.
Study NCT04971876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLR-2
Description: Initial injection of HLR-2 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 3mL per NLF.
Study NCT04971876 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HLR-3
Description: Initial injection of HLR-3 and optional TU after 4 weeks. Maximum injection volume for each treatment session is 4mL per cheek.
Study NCT00655031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Concentrate (POMx)
Description: 3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
Study NCT00655031 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
Study NCT02086539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Envelope
Study NCT01706211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRL 49653C
Description: BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
Study NCT01706211 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02086539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Priority Mail
Study NCT02086539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amazon
Study NCT01253655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212365
Description: Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
Study NCT00732303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed (Alimta) 500mg/\^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
Study NCT00732303 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.~The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks.
Study NCT03899766 — intervention group
Intervention type: OTHER
Intervention: Animal Assisted Intervention
Description: Operators of AAI and their dog meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
Study NCT03899766 — intervention group
Intervention type: OTHER
Intervention: Clowns
Description: Hospital clowns meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
Study NCT01697514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2940680
Description: Capsule administered orally.
Study NCT03899766 — intervention group
Intervention type: OTHER
Intervention: Musicians
Description: Musicians meet the child and his/her parent in the waiting room and facilitates interaction using their professional characteristics. The interaction continue in the venipuncture room during the procedure and at its conclusion; in fact, the operators accompany the child and his/her parent outside the venipuncture room, to not abruptly interrupt the interaction.
Study NCT03362021 — intervention group
Intervention type: PROCEDURE
Intervention: transvaginal oocyte retrieval
Description: sedation for oocyte retrieval
Study NCT02258828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
Study NCT02258828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00015977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PSA prostate cancer vaccine
Study NCT00015977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interleukin-12
Study NCT00414453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine patch 5%
Description: lidocaine 5% patch; 12 hours on, 12 hours off
Study NCT00414453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended-release oxycodone
Description: extended-release oxycodone titrating schedule
Study NCT00414453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo extended-release oxycodone pills
Description: placebo pills with titrating schedule
Study NCT00414453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo lidocaine patches
Description: used with extended release oxycodone group; used with placebo pills/placebo patches
Study NCT01050270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ondansetron
Description: 4mgs iv bolus
Study NCT01050270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetylcysteine
Description: 100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
Study NCT01050270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: acetylcysteine
Description: 150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
Study NCT03864926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus XR
Description: Envarsus XR is FDA approved for the prophylaxis of organ rejection in kidney transplant recipients converted from tacrolimus immediate-release formulations, in combination with other immunosuppressants. Envarsus XR, is designed to deliver tacrolimus more smoothly over the whole day.~Envarsus XR, a calcineurin-inhibitor immunosuppressant, is available for oral administration as extended-release tablets containing the equivalent of 0.75 mg, 1 mg, or 4 mg of anhydrous tacrolimus USP. Inactive ingredients include hypromellose USP, lactose monohydrate NF, polyethylene glycol NF, poloxamer NF, magnesium stearate NF, tartaric acid NF, butylated hydroxytoluene NF, and dimethicone NF. Tacrolimus is the active ingredient in ENVARSUS XR.
Study NCT03864926 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tacrolimus (generic; immediate release) is FDA approved for the prophylaxis of organ rejection in heart, kidney and liver transplant recipients.
Study NCT04193163 — intervention group
Intervention type: DEVICE
Intervention: Hip prosthesis - ESOP 2 cementless femoral stem
Description: ESOP 2 femoral stems are intended to be implanted in the femoral region during total hip arthroplasty in order to restore joint function.
Study NCT01960621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclodextrin
Description: intravenous